Beckman Coulter Life Sciences (Indianapolis, IN, USA) has increased the range of its products by acquiring Blue Ocean Biomedical (Pembroke Pines, FL, USA), a manufacturer of a line of automated flow cytometry systems and associated reagents.

Beckman Coulter develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. Their diagnostic systems are found in hospitals and other critical care settings around the world and generate data used by physicians to diagnose disease, make treatment decisions, and monitor patients. In the research sector, their instruments have been applied to complex biological problems including causes of disease and potential new therapies or drugs.

Blue Ocean Biomedical specializes in the development of innovative, automated “load & go” cell-analysis systems for immune monitoring and related applications. Blue Ocean has optimized their systems to address needs for specific moderate-to-high-demand applications where test results are desired in less time, with greater efficiency and at substantially lower costs.

The CR Series Systems are among Blue Ocean Biomedical’s top-of-the-line research tools. This instrument is a fully integrated, fluorescence-based, cellular analysis research system dedicated to running standardized immune monitoring panels. The design of the CR Series takes full advantage of advanced technology to introduce a fresh, innovative approach to automating the process of immune panel testing. The CR Series combines automated sample preparation - “load & go”- sample processing and analysis in one compact instrument.

“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president of Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We will be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”

The CR systems and reagents are currently not available in the US, and are for distribution in the European Union only.

Related Links:
Beckman Coulter Life Sciences
Blue Ocean Biomedical